Aluminum hydroxide

Identification

Name
Aluminum hydroxide
Accession Number
DB06723
Description

Aluminum hydroxide is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Thumb
Weight
Average: 78.0036
Monoisotopic: 77.989757403
Chemical Formula
AlH3O3
Synonyms
  • Aluminio hidróxido
  • Aluminium hydroxide
  • Aluminium hydroxide gel, dried
  • Aluminium hydroxide, dried
  • Aluminum hydroxide
  • Aluminum hydroxide gel, dried
  • Aluminum hydroxide, dried
  • Dried aluminium hydroxide
  • Dried aluminum hydroxide gel
External IDs
  • NSC-664400

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication

For relief of heartburn and acid indigestion.

Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Gastric-peptic disease occurs as a result of an imbalance between protective factors, such as mucus, bicarbonate, and prostaglandin secretion, and aggressive factors, such as hydrochloric acid, pepsin, and Helicobacter pylori (H. pylori). Antacids work by restoring acid-base balance, attenuating the pepsin activity and increasing bicarbonate and prostaglandin secretion.

Mechanism of action

Aluminum hydroxide is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. Aluminum hydroxide is slowly solubilized in the stomach and reacts with hydrochloric acid to form aluminum chloride and water. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins.

Absorption

Approximately 17-30% of the aluminum chloride formed is absorbed.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Not metabolized.

Route of elimination

Absorbed aluminum chloride is rapidly eliminated by the kidneys in patients with normal renal function.

Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetaminophenAluminum hydroxide can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetophenazineAluminum hydroxide can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Aluminum hydroxide.
AlfacalcidolThe serum concentration of Aluminum hydroxide can be increased when it is combined with Alfacalcidol.
AlimemazineAluminum hydroxide can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AllopurinolThe therapeutic efficacy of Allopurinol can be decreased when used in combination with Aluminum hydroxide.
AmphetamineThe serum concentration of Amphetamine can be increased when it is combined with Aluminum hydroxide.
AmprenavirAluminum hydroxide can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Ascorbic acidAscorbic acid can cause an increase in the absorption of Aluminum hydroxide resulting in an increased serum concentration and potentially a worsening of adverse effects.
AsunaprevirAluminum hydroxide can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
  • Avoid foods rich in citrate. Citrate may increase the absorption of aluminum and has the potential to cause toxicity.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Algeldrate03J11K103C1330-44-5SMYKVLBUSSNXMV-UHFFFAOYSA-K
Almagate568Z59H7ZJ66827-12-1MTEOMEWVDVPTNN-UHFFFAOYSA-E
Active Moieties
NameKindUNIICASInChI Key
Aluminum cationionic3XHB1D032B22537-23-1REDXJYDRNCIFBQ-UHFFFAOYSA-N
International/Other Brands
Alu-Cap (3M) / Amphojel (Wyeth)
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AlternagelLiquid600 mg/5mLOralMc Neil Consumer Pharmaceuticals Co.1990-01-012012-08-31US flag
Alu-tab Tab 600mgTabletOral3 M Pharmaceuticals, A Division Of 3 M Canada Company1993-12-312001-08-01Canada flag
Aluminum HydroxideLiquid320 mg/5mLOralAtlantic Biologicals Corps2005-02-01Not applicableUS flag
Aluminum HydroxideGel320 mg/5mLOralLLC Federal Solutions2013-08-12Not applicableUS flag
Aluminum HydroxideLiquid320 mg/5mLOralRugby2005-02-01Not applicableUS flag
ALUMINUM HYDROXIDE TABLETSTablet500 mgOralสำนักงานปลัดกระทรวงกลาโหม2004-04-20Not applicableThailand flag
Derma GranOintment0.275 g/100gTopicalMckesson Medical Surgical2013-11-12Not applicableUS flag
Derma GranOintment0.275 g/100gTopicalDerma Sciences2015-06-16Not applicableUS flag
DermadroxOintment1.356 g/113gTopicalGeritrex Llc2015-07-31Not applicableUS flag
Dermagran OintmentOintmentTopicalCanadian Medical Supply Inc.1987-12-311996-09-09Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Acid Gone AntacidAluminum hydroxide (95 mg/15mL) + Magnesium carbonate (358 mg/15mL)LiquidOralMajor2004-12-30Not applicableUS flag
Acid Gone Antacid Extra StrengthAluminum hydroxide (160 mg/1) + Magnesium carbonate (105 mg/1)Tablet, chewableOralMajor Pharmaceuticals2014-06-06Not applicableUS flag
Acid Gone Antacid Extra StrengthAluminum hydroxide (160 mg/1) + Magnesium carbonate (105 mg/1)Tablet, chewableOralAvera McKennan Hospital2015-07-092017-05-24US flag
Acidex Tc Oral SuspensionAluminum hydroxide (600 mg) + Magnesium hydroxide (300 mg)SuspensionOralGen Drug Company Ltd.Not applicable1997-05-30Canada flag
Advanced Antacid CherryAluminum hydroxide (400 mg/5mL) + Dimethicone (40 mg/5mL) + Magnesium hydroxide (400 mg/5mL)LiquidOralStrategic Sourcing Services LLC2012-06-01Not applicableUS flag
Advanced Antacid MintAluminum hydroxide (400 mg/10mL) + Dimethicone (40 mg/10mL) + Magnesium hydroxide (400 mg/10mL)SuspensionOralGoodsense2020-07-01Not applicableUS flag
Advanced Antacid Regular StrengthAluminum hydroxide (200 mg/5mL) + Dimethicone (20 mg/5mL) + Magnesium hydroxide (200 mg/5mL)LiquidOralNucare Pharmaceuticals,inc.2012-06-01Not applicableUS flag
Advanced Antacid Regular StrengthAluminum hydroxide (200 mg/5mL) + Dimethicone (20 mg/5mL) + Magnesium hydroxide (200 mg/5mL)LiquidOralStrategic Sourcing Services LLC2012-06-01Not applicableUS flag
Advanced Regular Strength AntacidAluminum hydroxide (200 mg/5mL) + Dimethicone (20 mg/5mL) + Magnesium hydroxide (200 mg/5mL)SuspensionOralWalgreen Company2015-01-01Not applicableUS flag
AHC Premium Intense Contour BalmAluminum hydroxide (0.45 g/50mL) + Adenosine (0.02 g/50mL) + Aluminium tristearate (0.04 g/50mL) + Arbutin (1 g/50mL) + Methicone (20 CST) (1.3 g/50mL) + Octinoxate (1.5 g/50mL) + Talc (2.05 g/50mL) + Titanium dioxide (3.96 g/50mL) + Zinc oxide (0.96 g/50mL)CreamTopicalCarver Korea Co.,Ltd.2014-01-152017-11-22US flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
AHC Premium Intense Contour BalmAluminum hydroxide (0.45 g/50mL) + Adenosine (0.02 g/50mL) + Aluminium tristearate (0.04 g/50mL) + Arbutin (1 g/50mL) + Methicone (20 CST) (1.3 g/50mL) + Octinoxate (1.5 g/50mL) + Talc (2.05 g/50mL) + Titanium dioxide (3.96 g/50mL) + Zinc oxide (0.96 g/50mL)CreamTopicalCarver Korea Co.,Ltd.2014-01-152017-11-22US flag
FIRST Mouthwash BLMAluminum hydroxide (3.15 g/236mL) + Dimethicone 410 (0.315 g/236mL) + Diphenhydramine hydrochloride (.2 g/.2g) + Lidocaine hydrochloride (1.6 g/1.6g) + Magnesium hydroxide (3.15 g/236mL)KitOralCutisPharma, Inc.2004-11-01Not applicableUS flag
Medi Hydro DP BB CreamAluminum hydroxide (0.07 mg/100mL) + Adenosine (0.00004 mg/100mL) + Nicotinamide (0.02 mg/100mL) + Stearic acid (0.05 mg/100mL) + Titanium dioxide (0.05 mg/100mL)CreamTopicalMbg Inc (Korea Institute of Science Development)2017-08-082018-08-08US flag

Categories

ATC Codes
A02AB02 — AlgeldrateA02AB01 — Aluminium hydroxideA02AD03 — Almagate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as post-transition metal hydroxides. These are inorganic compounds in which the largest oxoanion is hydroxide, and in which the heaviest atom not in an oxoanion is a post-transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Post-transition metal oxoanionic compounds
Sub Class
Post-transition metal hydroxides
Direct Parent
Post-transition metal hydroxides
Alternative Parents
Post-transition metal salts / Inorganic salts / Inorganic oxides / Inorganic hydrides
Substituents
Inorganic hydride / Inorganic oxide / Inorganic post-transition metal salt / Inorganic salt / Post-transition metal hydroxide
Molecular Framework
Not Available
External Descriptors
aluminium hydroxides (CHEBI:33130)

Chemical Identifiers

UNII
5QB0T2IUN0
CAS number
21645-51-2
InChI Key
WNROFYMDJYEPJX-UHFFFAOYSA-K
InChI
InChI=1S/Al.3H2O/h;3*1H2/q+3;;;/p-3
IUPAC Name
aluminium(3+) trihydroxide
SMILES
[OH-].[OH-].[OH-].[Al+3]

References

Synthesis Reference

Richard H. Goheen, William A. Nigro, Paul J. The, "Process for producing aluminum hydroxide of improved whiteness." U.S. Patent US4915930, issued November, 1933.

US4915930
General References
Not Available
KEGG Compound
C13391
PubChem Compound
10176082
PubChem Substance
175427087
ChemSpider
8351587
RxNav
81948
ChEBI
33130
ChEMBL
CHEMBL1200706
Wikipedia
Aluminum_hydroxide
AHFS Codes
  • 56:04.00 — Antacids and Adsorbents
  • 84:04.92 — Miscellaneous Local Anti-infectives

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionVaccine Responsiveness During Allergy De-sensitization Treatment / Vaccine Responsiveness in Allergy1
4CompletedTreatmentDyspepsia1
4CompletedTreatmentGastro-esophageal Reflux Disease (GERD)1
4RecruitingTreatmentSoft Tissue Sarcoma (STS)1
4Unknown StatusTreatmentEsophageal Cancers / Malignant Neoplasm of Stomach1
3CompletedPreventionPapillomavirus Infections / Papillomavirus Vaccines1
3CompletedSupportive CareMalignant Head and Neck Neoplasm / Mucositis / Radiation-Induced Disorder1
3CompletedTreatmentGastro-esophageal Reflux Disease (GERD)1
3CompletedTreatmentRhinoconjunctivitis, Allergic1
3TerminatedOtherGastro-esophageal Reflux Disease (GERD)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionIntra-articular; Oral0.6 g
Tablet; tablet, chewableOral200 mg
TabletOral152 mg
SuspensionOral2.39 g
TabletOral500 MG
Tablet, chewableOral500 MG
SuspensionOral200 ml
LiquidOral
Tablet, chewableOral
SuspensionOral200 mg
TabletOral200 mg
LiquidOral600 mg/5mL
TabletOral
TabletOral600 mg
SuspensionOral50 mg
GelOral320 mg/5mL
LiquidOral320 mg/5mL
Tablet, chewableOral300 mg
TabletOral100 mg
Injection, suspensionIntramuscular40 IU
SuspensionOral250 mg
SuspensionOral40 mg
TabletOral20 mg
SuspensionOral60 mg/15ml
Tablet30 mg
Tablet, chewableOral30 mg
GranuleOral400 mg
SuspensionOral0.4 g
OintmentTopical2.5 g/25g
OintmentTopical0.275 g/100g
OintmentTopical1.356 g/113g
OintmentTopical
OintmentTopical2 g/100g
Tablet, chewableOral50 mg
SuspensionOral32.501 g
Capsule, liquid filledOral100 mg
Tablet, chewableBuccal470 mg
SuspensionOral30 mg/5ml
SolutionOral
PowderOral
Tablet, chewableOral275 mg
KitOral
SuspensionOral1.75 g
SuspensionOral4 g
SuspensionOral6.3 g
Tablet, chewableOral200 mg
SuspensionOral26.49 g
TabletOral400 mg
SuspensionOral4000 mg
SuspensionOral6 g
SuspensionOral325 mg/5ml
Tablet, chewableOral325 mg
SuspensionOral261.44 mg
SuspensionOral13 g
SuspensionOral1.483 g
Tablet, chewableBuccal200 mg
GelBuccal; Oral4 g
SuspensionOral5.84 g
SuspensionOral20 mg
GranuleOral
LiquidTopical
Suspension50 mg/5ml
SuspensionOral300 mg/5ml
SuspensionOral262 mg
Powder, for suspensionOral6 g
SuspensionOral3.5 %
SuspensionOral3.65 g/100ml
SuspensionOral3.65 %
SuspensionOral4 %
SuspensionOral460 mg
Tablet, chewableOral400 mg
SuspensionOral200 mg/5ml
TabletOral25 mg
SuspensionOral4.5 g
Tablet, chewableOral250 mg
TabletOral300 mg
SuspensionOral250 mg/5ml
Injection, powder, for suspensionIntramuscular10 mcg/0.5ml
SuspensionOral
SuspensionOral10 mg/5ml
SuspensionOral8 g
Tablet, chewableOral0.279 g
Tablet, chewableOral234 mg
SuspensionOral6.15 g
SuspensionOral0.6 g
SuspensionOral300 mg
SuspensionOral80 mg
SuspensionOral400 mg/10ml
OintmentTopical
TabletOral
SuspensionOral3 g
GelOral80 mg/5ml
Suspension200 mg/5ml
SuspensionOral83.35 mg
CreamTopical
TabletOral30 mg
SuspensionOral57.97 g
SuspensionOral400 mg
TabletOral250 mg
SuspensionOral400 mg/5ml
LiquidOral8 % w/v
Powder
Tablet
Suspension
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP1.45ChemAxon
pKa (Strongest Acidic)4.07ChemAxon
Physiological Charge3ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity0 m3·mol-1ChemAxon
Polarizability1.78 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.5922
Blood Brain Barrier+0.8181
Caco-2 permeable-0.5094
P-glycoprotein substrateNon-substrate0.8274
P-glycoprotein inhibitor INon-inhibitor0.9892
P-glycoprotein inhibitor IINon-inhibitor0.9783
Renal organic cation transporterNon-inhibitor0.9433
CYP450 2C9 substrateNon-substrate0.8282
CYP450 2D6 substrateNon-substrate0.9
CYP450 3A4 substrateNon-substrate0.8206
CYP450 1A2 substrateNon-inhibitor0.9291
CYP450 2C9 inhibitorNon-inhibitor0.9148
CYP450 2D6 inhibitorNon-inhibitor0.9584
CYP450 2C19 inhibitorNon-inhibitor0.9447
CYP450 3A4 inhibitorNon-inhibitor0.9672
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9578
Ames testNon AMES toxic0.8393
CarcinogenicityCarcinogens 0.5918
BiodegradationReady biodegradable0.81
Rat acute toxicity1.7247 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9592
hERG inhibition (predictor II)Non-inhibitor0.9742
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on August 09, 2010 17:11 / Updated on March 04, 2021 11:02